Every Form 4 that Encompass Health Corp (EHC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EHC filings page.
Encompass Health Corp President & CEO Mark J. Tarr reported two tax-related share dispositions of Encompass Health common stock. On February 19, 43,378 shares were withheld at $107.15 per share, and on February 20, 1,797 shares were withheld at $106.55 per share.
According to the disclosure, these shares were withheld or surrendered to cover tax withholding obligations tied to the vesting of restricted stock, rather than open-market sales. After these transactions, Tarr directly owned 445,637 Encompass Health shares.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported two tax-related share dispositions in Encompass Health common stock. On February 19, 3,479 shares were withheld at $107.15 per share, and on February 20, 208 shares were withheld at $106.55 per share to cover tax withholding on vested restricted stock. After these transactions, Fay directly owned 101,922 shares of Encompass Health common stock.
Encompass Health Corp Chief Accounting Officer Andrew L. Price reported two tax-related share dispositions under an equity award. On February 19, 2026, 3,692 shares of Encompass Health common stock were surrendered at $107.15 per share, and on February 20, 2026, a further 228 shares were surrendered at $106.55 per share.
According to the footnote, these shares were withheld or surrendered to pay tax withholding obligations triggered by the vesting of related restricted stock, rather than sold as discretionary open-market trades. After these transactions, Price directly owned 75,405 shares of Encompass Health common stock.
Encompass Health Corp executive John Patrick Darby reported routine tax-related share dispositions. On February 19, 2026 and February 20, 2026, a total of 8,231 shares of Encompass Health common stock were withheld or surrendered to cover tax withholding obligations from vesting restricted stock. These transactions, coded “F,” reflect tax-withholding dispositions rather than open-market sales, and Darby continued to hold 91,353 shares directly after the most recent transaction.
Encompass Health Corp EVP & Chief Financial Officer Douglas E. Coltharp reported tax-related share dispositions in Encompass Health Common Stock. On February 20, 2026, 674 shares were withheld at $106.55 per share, and on February 19, 2026, 16,708 shares were withheld at $107.15 per share.
According to the footnote, these shares were withheld or surrendered to pay tax withholding obligations tied to the vesting of restricted stock, rather than sold in open-market transactions. After these dispositions, Coltharp directly owned 84,971 shares, with additional indirect holdings reported through irrevocable trusts and a spouse.
Encompass Health Corp EVP and COO Patrick William Tuer reported two tax-related share dispositions tied to restricted stock vesting. On February 19, 2026, 3,193 shares of Encompass Health common stock were withheld at $107.15 per share to cover tax obligations. On February 20, 2026, an additional 405 shares were withheld at $106.55 per share for the same purpose. After these non-open-market transactions, Tuer directly owned 26,488 shares of Encompass Health common stock.
Encompass Health Corp Chief Medical Officer Elissa Joy Charbonneau reported stock awards in the company’s common stock. On February 18, 2026, she acquired 8,914 shares at $0.00 per share as an annual restricted stock award under the 2025 Omnibus Performance Incentive Plan. On February 19, 2026, she acquired an additional 1,884 shares of restricted stock at $0.00 per share upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. Following these grants, she directly owned a total of 22,756.061 shares of Encompass Health common stock.
Encompass Health Corp executive John Patrick Darby, EVP, General Counsel & Secretary, reported two stock awards. On February 18, 2026, he acquired 17,720 shares of common stock, and on February 19, 2026, he received 2,154 restricted shares. Following these grants, he directly holds 99,584 shares of Encompass Health common stock.
Encompass Health Corp EVP & Chief Financial Officer Douglas E. Coltharp reported stock awards in Encompass Health Common Stock. On February 18, 2026, he acquired 37,588 shares as an annual restricted stock award pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan. On February 19, 2026, he acquired an additional 4,430 restricted shares upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. After these grants, his directly held stake increased to 102,353 shares, and the filing also notes indirect holdings through irrevocable trusts and his spouse.
Encompass Health Corp reported stock awards to Chief Accounting Officer Andrew L. Price. He acquired 8,178 shares of Encompass Health common stock on February 18, 2026 and 1,560 shares on February 19, 2026, both at a stated price of $0.00 per share.
The 8,178-share issuance reflects restricted stock delivered after meeting performance criteria from a February 23, 2023 performance share unit award. The 1,560-share grant is an annual restricted stock award under the company’s 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp reported that President and CEO Mark J. Tarr acquired company stock through equity awards, rather than open-market purchases. On February 19, 2026, he received 12,796 shares of Encompass Health common stock at $0.00 per share, increasing his direct holdings to 490,812 shares. This issuance of restricted stock resulted from meeting performance criteria under a performance share unit award granted on February 23, 2023.
On February 18, 2026, Tarr was also granted 100,946 shares of restricted stock at $0.00 per share, bringing his direct ownership to 478,016 shares immediately after that grant. This award was an annual restricted stock grant made under the corporation's 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported equity awards of company common stock. On February 18, 2026, he acquired 7,690 shares of restricted stock at $0.00 per share as a grant or award. On February 19, 2026, he acquired an additional 1,430 restricted shares at $0.00 per share.
The filing notes that 1,430 shares were issued upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. The 7,690-share transaction is described as an annual restricted stock award under the corporation's 2025 Omnibus Performance Incentive Plan. After these transactions, Fay directly owned over one hundred thousand Encompass Health common shares.
Encompass Health Corp executive Patrick William Tuer, EVP and Chief Operating Officer, reported acquiring company stock through equity awards. On February 18, 2026, he received 10,254 shares of Encompass Health common stock at a price of $0.00 per share as a grant or award, bringing his direct holdings to 26,296 shares.
On February 19, 2026, he received an additional 3,790 restricted shares at $0.00 per share, increasing his direct ownership to 30,086 shares. Footnotes state that one issuance reflects satisfaction of performance criteria from a February 23, 2023 performance share unit award, and the other is an annual restricted stock award under the 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp. President & CEO Mark J. Tarr, who is also a director, reported multiple open-market sales of company common stock on February 11, 2026.
He sold a total of 150,000 shares at weighted-average prices ranging from $107.47 to $113.58 per share, and directly owned 377,070 shares of Encompass Health common stock after these transactions.
Encompass Health Corp. executive vice president and chief operating officer Patrick William Tuer sold 2,804 shares of Encompass Health common stock in an open market transaction on February 10, 2026. The shares were sold at a weighted average price of $107.62 per share, in multiple trades ranging from $107.55 to $107.73. Following this sale, Tuer directly beneficially owns 16,042 shares of Encompass Health common stock.
Encompass Health Corp reported an equity award to director Cain A. Hayes. On January 30, 2026, Hayes received 457 shares of Encompass Health common stock at a price of $0 per share, granted as restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan. Following this award, Hayes directly beneficially owns 457 shares of Encompass Health common stock.
Encompass Health Corp director Greg D. Carmichael reported receiving 28 shares of Encompass Health common stock on January 15, 2026, recorded at a price of $0 per share as a stock-based award. Following this transaction, he beneficially owned 18,659 shares directly.
The filing explains that this award reflects additional restricted stock units credited to non-employee directors in connection with common stock dividend payments. On January 15, 2026, Encompass Health paid a $0.19 per share dividend when the stock’s closing price was $102.80, and the 28 RSUs reported are tied to that dividend-related accrual.
Encompass Health Corp director Joan E. Herman reported an automatic equity award tied to the company’s common stock dividend. On January 15, 2026, she received 87 additional shares of Encompass Health common stock at a price of $0 per share, reflecting dividend-equivalent credits under outstanding restricted stock unit award agreements.
The filing notes Encompass Health paid a $0.19 per share dividend on its common stock on that date, when the stock’s closing price was $102.80. Following this award, Herman beneficially owned 47,839 shares of Encompass Health common stock directly.
Encompass Health Corp director reports dividend-linked RSU award
Encompass Health Corp director Leslye G. Katz filed a Form 4 reporting an automatic award of 87 restricted stock units (RSUs) of Encompass Health common stock on January 15, 2026. The RSUs were credited at a price of $0 per unit, increasing her directly held beneficial ownership to 47,839 shares.
According to the footnote, non-employee directors receive additional RSUs in connection with common stock dividend payments. On January 15, 2026, Encompass Health paid a cash dividend of $0.19 per share, and the RSU credit was calculated using the closing stock price of $102.80 on the dividend payment date.
Encompass Health Corp director Kevin J. O'Connor reported a small dividend-related equity grant. On January 15, 2026, he acquired 17 shares of Encompass Health common stock at a reported price of $0, bringing his directly held stake to 9,912 shares. According to the award terms, this reflects restricted stock units credited to non-employee directors in connection with common stock dividend payments. For this dividend, Encompass Health paid $0.19 per share, and the closing stock price on the payment date was $102.80, which was used to calculate the number of RSUs credited.
Encompass Health Corp director Nancy M. Schlichting reported an automatic award of 40 shares of Encompass Health common stock on January 15, 2026. The shares were credited at a price of $0.00 per share as restricted stock units tied to the company’s common stock dividend. The footnote explains that non-employee directors receive additional RSUs whenever dividends are paid, based on the number of existing RSUs, the per-share dividend of $0.19, and the closing price of $102.80 on the dividend payment date. Following this transaction, Schlichting beneficially owned 21,259 shares of Encompass Health common stock in direct form.
Encompass Health Corp director Terrance Williams reported a routine equity award linked to the company’s dividend. On January 15, 2026, he acquired 28 shares of Encompass Health common stock at a stated price of $0, bringing his total beneficial ownership to 15,169 shares.
According to the award agreements, additional restricted stock units are credited to each non-employee director when Encompass Health pays common stock dividends. For this dividend, the company paid $0.19 per share and the stock’s closing price was $102.80, resulting in an RSU award associated with that dividend payment.
Encompass Health Corp director Edward M. Christie III reported acquiring additional company stock on January 15, 2026. He received 9 shares of Encompass Health common stock at $0.00 per share as part of an award of restricted stock units tied to a cash dividend of $0.19 per share, based on a closing price of $102.80.
On the same date, he acquired a further 269 shares at a weighted average price of $102.82 per share through the company’s Directors Deferred Stock Investment Plan, which reinvests deferred director fees and related dividends in common stock. Following these transactions, he directly held 7,182 shares of Encompass Health common stock.
Encompass Health Corp director Christopher R. Reidy reported routine share acquisitions tied to director compensation arrangements. On January 15, 2026, he received 19 shares of Encompass Health common stock valued at $0 per share through an award of restricted stock units connected to a $0.19-per-share dividend. On the same date, he acquired an additional 346 shares at a weighted average price of $103.07 per share through the company’s Directors Deferred Stock Investment Plan, which uses deferred director fees and reinvested dividends to purchase stock in the market. Following these transactions, Reidy directly beneficially owned 15,450 shares of Encompass Health common stock.
Encompass Health (EHC) director Greg D. Carmichael reported an automatic award of 23 restricted stock units (RSUs) on 10/15/2025. The filing shows these were credited at a $0 price as dividend-equivalent RSUs tied to the company’s common stock dividend program for non-employee directors.
According to the footnote, the RSUs credited equal the product of RSUs held on the dividend record date and the $0.19 per-share dividend, divided by the stock’s $123.65 closing price on the payment date. Following the transaction, the form lists 18,631 securities beneficially owned in direct form.
Encompass Health (EHC) reported a director’s Form 4 activity on 10/15/2025. The director received 7 RSUs credited in connection with a common stock dividend and acquired 223 shares through the Directors Deferred Stock Investment Plan.
The RSUs were credited based on the company’s $0.19 per share dividend and a closing price of $123.65. The 223 shares were purchased at a weighted average price of $123.21. Following these transactions, the director beneficially owns 6,904 shares directly.
Encompass Health (EHC) reported an insider equity award tied to its dividend policy. A company director acquired 73 restricted stock units at a stated price of $0 on October 15, 2025, reflecting dividend-equivalent RSUs credited under existing award agreements. Following the transaction, the director beneficially owned 47,752 shares/units directly.
The RSU credit was calculated using a $0.19 per-share dividend and the $123.65 closing price on the payment date, per the explanation of responses.
Encompass Health (EHC) reported an insider equity change: director Leslye G. Katz acquired 73 restricted stock units on 10/15/2025 at $0 per unit. The award reflects dividend-equivalent RSUs tied to a $0.19 common stock dividend, calculated using the $123.65 closing price on the payment date. Following the transaction, Katz beneficially owned 47,752 Encompass Health common shares.
Encompass Health (EHC) director Kevin J. O’Connor reported an automatic credit of 14 restricted stock units (RSUs) on 10/15/2025. The award reflects dividend equivalents under outstanding RSU agreements tied to the company’s common stock dividend.
Per the footnote, the number of RSUs credited equals the product of the RSUs held on the dividend record date and the $0.19 per-share dividend, divided by the $123.65 closing price on the dividend payment date. The transaction was recorded at $0. Following this entry, securities beneficially owned were listed as 9,895, held directly.
Encompass Health (EHC) director Form 4: On 10/15/2025, a non-employee director reported two acquisitions. First, 16 restricted stock units were credited at $0 pursuant to dividend-equivalent terms tied to outstanding RSUs. Second, 288 common shares were purchased at a weighted average price of $123.23 in multiple trades ranging from $123.19 to $123.24.
The RSU credit relates to a $0.19 per-share common dividend paid on October 15, 2025, using the closing price of $123.65 to calculate units. The share purchase reflects the Directors Deferred Stock Investment Plan, which uses deferred director fees and reinvested dividends to buy shares in the market. Following these transactions, direct beneficial ownership reported in Table I was 15,085 shares.
Encompass Health (EHC) director Nancy M. Schlichting reported an automatic credit of 33 restricted stock units (RSUs) on 10/15/2025. The award stems from dividend equivalents pursuant to outstanding RSU award agreements, reflecting Encompass Health’s common stock dividend of $0.19 per share and a closing price of $123.65 on the payment date. The transaction is recorded at $0 as it was an accrual, not a market purchase.
Following this transaction, Schlichting beneficially owns 21,219 shares, held directly.
Encompass Health (EHC) director Terrance Williams reported an automatic credit of 23 restricted stock units on 10/15/2025. The award reflects dividend-equivalent RSUs under outstanding agreements, calculated using a $0.19 per-share dividend and the $123.65 closing price on the dividend payment date. The transaction was recorded at $0 per unit. Following this entry, Williams beneficially owned 15,141 securities in direct ownership.